TY - JOUR
T1 - Atlas of axial spondyloarthritis in Spain 2017: Study design and population
AU - Garrido-Cumbrera, Marco
AU - Navarro-Compán, Victoria
AU - Zarco, Pedro
AU - Collantes-Estévez, Eduardo
AU - Gálvez-Ruiz, David
AU - Braçe, Olta
AU - Chacón García, Jorge
AU - Blanch Mur, Carles
AU - Costa Ferrer, Angels
AU - Hidalgo Vega, Alvaro
AU - Plazuelo Ramos, Pedro
AU - Gratacós Masmitja, Jordi
N1 - Copyright © 2018 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.
PY - 2019/5/1
Y1 - 2019/5/1
N2 - © 2018 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología Objective: Atlas of Axial Spondyloarthritis in Spain 2017 aims to better understand the reality of the patients suffering from this disease from an integrated approach. Methods: The Atlas 2017 based its results on an extensive cross-sectional patient survey conducted in Spain (2016), validated by a multidisciplinary group of experts on spondyloarthritis. Results: Data from 680 patients with axSpA were obtained, most of them suffered from AS, were HLA-B27 positive, older than 45 years, and live as part of a couple. A large percentage had university studies, were disabled and members of a patient association. Patients reported a diagnostic delay of 8.5 years, high disease activity (BASDAI 5.5 ± 2.2), moderate-important stiffness (61.0%), medium-high functional limitation (74.9%), and psychological distress (GHQ 5.7 ± 4.5). A total of 54.7% reported taking NSAIDs, 28.4% DMARDs, 36.3% biological therapy and 32.2% were not receiving pharmacological treatment. Conclusions: The Atlas survey data reveals still a long diagnostic delay, high disease activity, psychological distress, while an important proportion could be undertreated.
AB - © 2018 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología Objective: Atlas of Axial Spondyloarthritis in Spain 2017 aims to better understand the reality of the patients suffering from this disease from an integrated approach. Methods: The Atlas 2017 based its results on an extensive cross-sectional patient survey conducted in Spain (2016), validated by a multidisciplinary group of experts on spondyloarthritis. Results: Data from 680 patients with axSpA were obtained, most of them suffered from AS, were HLA-B27 positive, older than 45 years, and live as part of a couple. A large percentage had university studies, were disabled and members of a patient association. Patients reported a diagnostic delay of 8.5 years, high disease activity (BASDAI 5.5 ± 2.2), moderate-important stiffness (61.0%), medium-high functional limitation (74.9%), and psychological distress (GHQ 5.7 ± 4.5). A total of 54.7% reported taking NSAIDs, 28.4% DMARDs, 36.3% biological therapy and 32.2% were not receiving pharmacological treatment. Conclusions: The Atlas survey data reveals still a long diagnostic delay, high disease activity, psychological distress, while an important proportion could be undertreated.
KW - Axial spondyloarthritis
KW - Burden of disease
KW - Healthcare management
KW - Patient perspective
UR - http://www.mendeley.com/research/atlas-axial-spondyloarthritis-spain-2017-study-design-population
U2 - 10.1016/j.reuma.2018.08.003
DO - 10.1016/j.reuma.2018.08.003
M3 - Article
C2 - 30292853
SN - 1699-258X
VL - 15
SP - 127
EP - 132
JO - Reumatologia Clinica
JF - Reumatologia Clinica
IS - 3
ER -